We serve Chemical Name:4-Bromo-N-(4-bromophenyl)-N-phenylaniline CAS:81090-53-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Bromo-N-(4-bromophenyl)-N-phenylaniline
CAS.NO:81090-53-1
Synonyms:4-Bromo-N-(4-bromophenyl)-N-phenylaniline;Benzenamine, 4-bromo-N-(4-bromophenyl)-N-phenyl-;MFCD00060104;Dibromotriphenylamine
Molecular Formula:C18H13Br2N
Molecular Weight:403.111
HS Code:2921440000
Physical and Chemical Properties:
Melting point:69ºC
Boiling point:470.7±30.0 °C at 760 mmHg
Density:1.6±0.1 g/cm3
Index of Refraction:1.679
PSA:3.24000
Exact Mass:400.941467
LogP:7.76
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 4-Bromo-N-(4-bromophenyl)-N-phenylaniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Dibromotriphenylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00060104 Use and application,Dibromotriphenylamine technical grade,usp/ep/jp grade.
Related News: As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 4-Bromo-N-(4-bromophenyl)-N-phenylaniline manufacturer If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role. 4-Bromo-N-(4-bromophenyl)-N-phenylaniline supplier The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun. 4-Bromo-N-(4-bromophenyl)-N-phenylaniline vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 4-Bromo-N-(4-bromophenyl)-N-phenylaniline factory A week before Eli Lilly (LLY.N) disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters.
